Statements (78)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:AveXis,_Inc.
Acquired AveXis for $8.7 billion. |
| gptkbp:advocacy |
support_for_SMA_awareness.
|
| gptkbp:clinicalTrials |
gptkb:SMA_Type_1
focus on patient needs. Phase 1/2. Phase 3 trials. achieved success in trials. advances therapeutic development. employs innovative trial designs. focus on improving patient outcomes. increased participation in trials. innovative approaches to trials. ongoing studies for new therapies. positive results in trials. published in peer-reviewed journals. Spinal_Muscular_Atrophy_(SMA). |
| gptkbp:collaborations |
gptkb:University_of_Pennsylvania
GSK_for_gene_therapy_research. |
| gptkbp:community_service |
improves access to therapies.
initiatives to improve access to therapies. offers support for families. |
| gptkbp:communityEngagement |
active in patient communities.
|
| gptkbp:communityPartnerships |
collaborates with healthcare organizations.
collaborates with healthcare providers. recognized for scientific leadership. |
| gptkbp:economicImpact |
aims to improve health outcomes.
|
| gptkbp:evaluates |
demonstrated in clinical studies.
|
| gptkbp:fieldOfTechnology |
active participant in the biotech industry.
|
| gptkbp:focusArea |
gene therapy
|
| gptkbp:founded |
2018
|
| gptkbp:futurePlans |
expand gene therapy portfolio.
|
| gptkbp:globalPresence |
operates in multiple countries.
|
| gptkbp:goal |
develop innovative gene therapies.
|
| gptkbp:hasPopulation |
children_with_SMA.
|
| gptkbp:hasPrograms |
composed of leading experts.
|
| gptkbp:headquarters |
gptkb:Boulder,_Colorado
|
| gptkbp:healthcare |
drives innovation in healthcare.
engages with patient communities. provides resources for patients. works with advocacy groups. |
| gptkbp:historicalResearch |
conducts extensive research.
|
| https://www.w3.org/2000/01/rdf-schema#label |
Novartis Gene Therapies
|
| gptkbp:impact |
one-time gene replacement therapy.
|
| gptkbp:innovation |
focus on cutting-edge gene therapies.
|
| gptkbp:internationalCooperation |
works with global partners.
|
| gptkbp:investmentFocus |
$8.7 billion in gene therapy research.
|
| gptkbp:keyPeople |
gptkb:David_Lennon
|
| gptkbp:leadership |
experienced team in gene therapy.
|
| gptkbp:leads |
Zolgensma.
|
| gptkbp:market |
rare genetic disorders.
|
| gptkbp:marketingStrategy |
Zolgensma_in_2019.
|
| gptkbp:marketSegment |
focus on rare diseases.
|
| gptkbp:mission |
transform the lives of patients with genetic diseases.
|
| gptkbp:parentCompany |
Novartis AG
|
| gptkbp:partnerships |
with biotech firms.
The_Children's_Hospital_of_Philadelphia. |
| gptkbp:partOf |
gptkb:Novartis_Pharmaceuticals_Corporation
|
| gptkbp:productionCompany |
develops manufacturing capabilities.
|
| gptkbp:products |
Zolgensma
|
| gptkbp:regulatoryBody |
EMA approval for Zolgensma.
|
| gptkbp:regulatoryCompliance |
FDA approval for Zolgensma
adheres to global regulations. files for new therapies. |
| gptkbp:research |
significant investment in gene therapy.
supports funding for research. |
| gptkbp:research_areas |
neuromuscular diseases
|
| gptkbp:researchAndDevelopment |
contributes to advancements in biotechnology.
|
| gptkbp:researchFocus |
AAV-based gene therapies
|
| gptkbp:researchInterest |
with academic institutions.
supports innovative research. contributes to gene therapy literature. with leading research institutions. |
| gptkbp:safetyFeatures |
favorable in clinical trials.
|
| gptkbp:technology |
invests in new technologies.
Adeno-Associated_Virus_(AAV)_vector_technology. |
| gptkbp:tributaryOf |
multiple gene therapy candidates.
|